StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) stock

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3024% above fair value
$1443.50+16.22 (+1.14%)

Close on Nov 13, 2026Market cap $1.36TP/E 46.9Yield 0.43%

Eli Lilly cash

Cash and short-term investments held at the end of each period.

Eli Lilly's cash was $4.89B at Sep 30, 2026. For fiscal 2025 it was $7.27B, up 112.3% from the year before. Over ten years it grew 5.0% a year on average. The highest annual figure on record is $8.03B in fiscal 2017.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.27B+112.3%
FY2024Dec 31, 2024$3.42B+16.9%
FY2023Dec 31, 2023$2.93B+32.4%
FY2022Dec 31, 2022$2.21B-43.4%
FY2021Dec 31, 2021$3.91B+6.2%
FY2020Dec 31, 2020$3.68B+51.0%
FY2019Dec 31, 2019$2.44B-67.1%
FY2018Dec 31, 2018$7.41B-7.8%
FY2017Dec 31, 2017$8.03B+33.0%
FY2016Dec 31, 2016$6.04B+35.6%
FY2015Dec 31, 2015$4.45B-7.8%
FY2014Dec 31, 2014$4.83B-10.6%
FY2013Dec 31, 2013$5.40B-5.0%
FY2012Dec 31, 2012$5.68B-17.6%
FY2011Dec 31, 2011$6.90B+2.5%
FY2010Dec 31, 2010$6.73B+49.6%
FY2009Dec 31, 2009$4.50B-24.1%
FY2008Dec 31, 2008$5.93B+84.0%
FY2007Dec 31, 2007$3.22B+3.6%
FY2006Dec 31, 2006$3.11B–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$4.89B-50.7%
Q2 FY2026Jun 30, 2026$8.95B+152.4%
Q1 FY2026Mar 31, 2026$5.28B+64.0%
Q4 FY2025Dec 31, 2025$7.27B+112.3%
Q3 FY2025Sep 30, 2025$9.91B+181.8%
Q2 FY2025Jun 30, 2025$3.55B+5.4%
Q1 FY2025Mar 31, 2025$3.22B+24.5%
Q4 FY2024Dec 31, 2024$3.42B+16.9%
Q3 FY2024Sep 30, 2024$3.52B+41.1%
Q2 FY2024Jun 30, 2024$3.36B+18.9%
Q1 FY2024Mar 31, 2024$2.59B-29.5%
Q4 FY2023Dec 31, 2023$2.93B+32.4%
Q3 FY2023Sep 30, 2023$2.49B-9.1%
Q2 FY2023Jun 30, 2023$2.83B+3.4%
Q1 FY2023Mar 31, 2023$3.67B+42.9%
Q4 FY2022Dec 31, 2022$2.21B-43.4%
Q3 FY2022Sep 30, 2022$2.74B-28.3%
Q2 FY2022Jun 30, 2022$2.74B-16.3%
Q1 FY2022Mar 31, 2022$2.57B-15.8%
Q4 FY2021Dec 31, 2021$3.91B+6.2%
Q3 FY2021Sep 30, 2021$3.83B+5.4%
Q2 FY2021Jun 30, 2021$3.27B+37.0%
Q1 FY2021Mar 31, 2021$3.05B+71.7%
Q4 FY2020Dec 31, 2020$3.68B+51.0%
Q3 FY2020Sep 30, 2020$3.63B+53.3%
Q2 FY2020Jun 30, 2020$2.39B+11.7%
Q1 FY2020Mar 31, 2020$1.78B-76.0%
Q4 FY2019Dec 31, 2019$2.44B-73.0%
Q2 FY2019Jun 30, 2019$2.37B-65.7%
Q1 FY2019Mar 31, 2019$2.14B-55.4%
Q4 FY2018Dec 31, 2018$7.41B-7.8%
Q3 FY2018Sep 30, 2018$9.04B+30.1%
Q2 FY2018Jun 30, 2018$6.91B+27.2%
Q1 FY2018Mar 31, 2018$4.79B+36.6%
Q4 FY2017Dec 31, 2017$8.03B+33.0%
Q3 FY2017Sep 30, 2017$6.94B–
Q2 FY2017Jun 30, 2017$5.43B–
Q1 FY2017Mar 31, 2017$3.51B–
Q4 FY2016Dec 31, 2016$6.04B–

More Eli Lilly figures

See a number that looks wrong?